Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Management of Multiple Myeloma
On one hand the availability of various classes of agents has significantly improved patient outcomes but on the other presents challenges to clinicians in terms of selecting optimal frontline therapy for MM, determining the nature and duration of maintenance, and selecting the ideal sequence of therapy at relapse. The key to maximizing treatment and supportive care outcomes for patients with MM lies in careful choice of individualized treatment regimens along with early recognition and management of treatment or MM-associated adverse events. Many factors need to be considered when determining the optimal MM treatment: age, prognostic factors, comorbidities, toxicity profiles, response to prior therapy, previous relapses and patient preferences. Moreover, the variety of available supportive care measures targeting adverse symptoms related to MM or MM therapy have to be tailored to a specific patient. Clinicians need to be aware of the range of factors involved in managing the treatment and supportive care of patients with MM. It is important for clinicians to discuss practical patient examples and the rationale for the various treatment choices based on expert experience and recent data from trials to aid the decision-making process for clinicians treating patients with myeloma.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Evaluate the benefits and risks associated with therapies and use evidence-based data and patient characteristics to select an optimal management strategy for patients with newly diagnosed MM.
- Analyze efficacy and tolerability of therapies for the management of relapsed MM and effectively counsel patients.
- Use evidence-based data to manage bone disease and other complications in patients with MM.
Natalie S. Callander, MD
University of Wisconsin Carbone Cancer Center
Michelle L. Lakner, MSN, APNP
University of Wisconsin Carbone Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Natalie S. Callander, MD
Michelle L. Lakner, MSN, APNP
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Sarah Sinclair; Kathy Ann Smith, CHCP
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP (employed by NCCN until 12/3/2018)
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Katherine Pierce (employed by NCCN until 11/16/2018)
Boston Scientific Corporation: Equity Interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.78 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-061-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 6/5/2020. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.78 ANCC contact hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing